Sign In
Buy IONS
$73.82
+0.85 (+1.16%)
At Close: Jun 03, 2026
Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates
09:55am, Wednesday, 03'rd May 2023
Ionis Pharmaceuticals (IONS) came out with a quarterly loss of $0.87 per share versus the Zacks Consensus Estimate of a loss of $1. This compares to loss of $0.46 per share a year ago.
Biotech/Drug Stocks' Q1 Earnings Due May 3: UTHR, PCRX & More
02:32pm, Tuesday, 02'nd May 2023
Let us take a look at what's in store for biotech/drug stocks UTHR, PCRX, CORT, AMRN and IONS, which are scheduled to report on May 3.
3 Biotech Stocks to Sell Before They're 6 Feet Under
02:37pm, Monday, 24'th Apr 2023
In a high-interest-rate environment, cash is king. All biotech companies will need to continue spending to finance their R&D.
Ionis to hold first quarter 2023 financial results webcast
07:05am, Thursday, 20'th Apr 2023
Webcast scheduled for Wednesday, May 3 at 11:30 a.m. Eastern Time CARLSBAD, Calif.
Could This Rare-Disease Drug Candidate Become a Blockbuster?
09:15am, Wednesday, 19'th Apr 2023
AstraZeneca and Ionis recently shared promising phase 3 clinical trials for eplontersen. If approved, the drug candidate could top $1 billion in annual sales -- split between the two companies.
Ionis to present at upcoming investor conferences
07:05am, Tuesday, 28'th Mar 2023
CARLSBAD, Calif. , March 28, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced its participation in fireside chats at the following investor conferences: Guggenheim Virtu
Ionis (IONS) Posts New Upbeat Data From Amyloidosis Drug Study
12:59pm, Monday, 27'th Mar 2023
Ionis (IONS) reports positive long-term phase III study data, supporting the benefits of eplontersen as a treatment for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).
Why Is Ionis Pharmaceuticals (IONS) Down 8.4% Since Last Earnings Report?
12:59pm, Friday, 24'th Mar 2023
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock?
Ionis Rockets As Biogen-Partnered ALS Drug Wins Key Endorsement
09:25am, Thursday, 23'rd Mar 2023
Ionis stock jumped Thursday after an FDA panel offered a mixed view of its Biogen-partnered drug for ALS. The post Ionis Rockets As Biogen-Partnered ALS Drug Wins Key Endorsement appeared first on Inv
Wall Street predicts approval for another ALS drug
11:45am, Tuesday, 21'st Mar 2023
It appears likely that a new drug to treat amyotrophic lateral sclerosis (ALS) will get approval in the U.S. Regulators shared their thinking ahead of an advisory committee meeting.
Ionis to present at upcoming investor conferences
07:05am, Tuesday, 28'th Feb 2023
CARLSBAD, Calif. , Feb. 28, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will present at the following investor conferences: Cowen 43rd Annual Health
Ionis (IONS) Q4 Earnings Top Estimates, Sales Lag, Stock Down
10:32am, Thursday, 23'rd Feb 2023
Ionis (IONS) Q4 loss is narrower than expected. However, sales miss estimates.
Ionis Pharmaceuticals, Inc. (IONS) Q4 2022 Earnings Call Transcript
02:57pm, Wednesday, 22'nd Feb 2023
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Q4 2022 Results Conference Call February 22, 2023 11:30 AM ET Company Participants Wade Walke - SVP, IR Brett Monia - CEO Beth Hougen - CFO Eugene Schneider
Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Misses Revenue Estimates
09:47am, Wednesday, 22'nd Feb 2023
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 65.09% and 3.82%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock
Earnings Preview: Ionis Pharmaceuticals (IONS) Q4 Earnings Expected to Decline
11:17am, Wednesday, 15'th Feb 2023
Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
